HighTower Advisors’s VistaGen Therapeutics VTGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $11.8K | Hold |
20,628
| – | – | ﹤0.01% | 3781 |
|
|
2025
Q4 | $13.7K | Sell |
20,628
-200
| -1% | -$722 | ﹤0.01% | 3627 |
|
|
2025
Q3 | $73.9K | Hold |
20,828
| – | – | ﹤0.01% | 3583 |
|
|
2025
Q2 | $41.7K | Hold |
20,828
| – | – | ﹤0.01% | 3564 |
|
|
2025
Q1 | $52.1K | Hold |
20,828
| – | – | ﹤0.01% | 3447 |
|
|
2024
Q4 | $61.4K | Hold |
20,828
| – | – | ﹤0.01% | 3435 |
|
|
2024
Q3 | $64K | Buy |
+20,828
| New | +$71.1K | ﹤0.01% | 3381 |
|
|
2023
Q2 | – | Sell |
-4,042
| Closed | -$15K | – | 3718 |
|
|
2023
Q1 | $15K | Hold |
4,042
| – | – | ﹤0.01% | 3172 |
|
|
2022
Q4 | $12K | Sell |
4,042
-1,200
| -23% | -$4.52K | ﹤0.01% | 3168 |
|
|
2022
Q3 | $23K | Sell |
5,242
-161
| -3% | -$1.6K | ﹤0.01% | 2963 |
|
|
2022
Q2 | $142K | Hold |
5,403
| – | – | ﹤0.01% | 2711 |
|
|
2022
Q1 | $200K | Buy |
5,403
+867
| +19% | +$37.8K | ﹤0.01% | 2843 |
|
|
2021
Q4 | $266K | Hold |
4,536
| – | – | ﹤0.01% | 2552 |
|
|
2021
Q3 | $372K | Hold |
4,536
| – | – | ﹤0.01% | 2276 |
|
|
2021
Q2 | $429K | Buy |
4,536
+333
| +8% | +$24.7K | ﹤0.01% | 2136 |
|
|
2021
Q1 | $269K | Buy |
+4,203
| New | +$281K | ﹤0.01% | 2379 |
|
|
2020
Q4 | – | Sell |
-4,411
| Closed | -$92K | – | 2884 |
|
|
2020
Q3 | $92K | Hold |
4,411
| – | – | ﹤0.01% | 2243 |
|
|
2020
Q2 | $70K | Hold |
4,411
| – | – | ﹤0.01% | 2173 |
|
|
2020
Q1 | $58K | Hold |
4,411
| – | – | ﹤0.01% | 1996 |
|
|
2019
Q4 | $91K | Hold |
4,411
| – | – | ﹤0.01% | 2085 |
|
|
2019
Q3 | $142K | Sell |
4,411
-1
| -0% | -$22 | ﹤0.01% | 2125 |
|
|
2019
Q2 | $96K | Buy |
4,412
+3,377
| +326% | +$89.6K | ﹤0.01% | 2166 |
|
|
2019
Q1 | $39K | Sell |
1,035
-8
| -0.8% | -$349 | ﹤0.01% | 2137 |
|
|
2018
Q4 | $46K | Buy |
1,043
+252
| +32% | +$13.7K | ﹤0.01% | 2038 |
|
|
2018
Q3 | $34K | Hold |
791
| – | – | ﹤0.01% | 2149 |
|
|
2018
Q2 | $32K | Buy |
791
+86
| +12% | +$2.99K | ﹤0.01% | 2096 |
|
|
2018
Q1 | $19K | Buy |
705
+31
| +5% | +$1.15K | ﹤0.01% | 2057 |
|
|
2017
Q4 | $22K | Hold |
674
| – | – | ﹤0.01% | 2156 |
|
|
2017
Q3 | $32K | Hold |
674
| – | – | ﹤0.01% | 2110 |
|
|
2017
Q2 | $38K | Hold |
674
| – | – | ﹤0.01% | 2047 |
|
|
2017
Q1 | $39K | Hold |
674
| – | – | ﹤0.01% | 1941 |
|
|
2016
Q4 | $75K | Hold |
674
| – | – | ﹤0.01% | 1796 |
|
|
2016
Q3 | $86K | Hold |
674
| – | – | ﹤0.01% | 1750 |
|
|
2016
Q2 | $79K | Buy |
+674
| New | +$77.2K | ﹤0.01% | 1617 |
|
Other funds holding VTGN
O
TCM
VCM
ACM
IC
HighTower Advisors's VTGN Position: Q1 2026 in Review
HighTower Advisors held its VistaGen Therapeutics (VTGN) position steady in Q1 2026 at 20,628 shares worth $11.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3781.
HighTower Advisors first reported a position in VTGN in Q2 2016 and has held it in 34 quarters since. The position peaked at $429K in Q2 2021. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.
- HighTower Advisors held 20,628 shares of VistaGen Therapeutics worth $11.8K as of Q1 2026.
- HighTower Advisors left its VistaGen Therapeutics share count unchanged in Q1 2026.
- VistaGen Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #3781 holding.
- HighTower Advisors first reported a position in VistaGen Therapeutics in Q2 2016 and has held it in 34 quarters since.
- HighTower Advisors's VistaGen Therapeutics position peaked at $429K in Q2 2021.
- 56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.
Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.